OBJ says Dermaportation drug-delivery technology proven in human trial

By Elaine Rigoli

Tampa, Fla., April 19 - OBJ Ltd. said Wednesday that Curtin University in western Australia successfully completed a blinded, placebo-controlled human pilot study into the effects of the company's drug-delivery technology on the speed of onset of a commercially available Tetracaine local anesthetic.

The trial concluded that the anesthetic effects of Tetracaine gel was increased by Dermaportation in all volunteer subjects, demonstrating that Dermaportation enhanced the penetration of the local anesthetic, according to a news release.

The company said this is the first time the OBJ patch has been used on human skin.

A full clinical trial is expected later this year, the release said.

Based in Perth, Australia, OBJ is a drug-delivery technology company that specializes in transdermal technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.